|
|
|
| Terlipressin versus placebo in living donor liver transplantation |
| Paschalis Gavriilidis a , ∗, Ernest Hidalgo b , Robert P Sutcliffe a , Keith J Roberts a |
a Department of Hepato-Pancreato-Biliary and Liver Transplant surgery, Queen Elizabeth University Hospitals Birmingham NHS Foundation Trust,
Birmingham B15 2TH, UK
b Department of Hepato-Pancreatico-Biliary Surgery and Transplantation, Hospital Universitari Vall d’Hebron, Barcelona 08035, Spain
∗ Corresponding author.
E-mail address: pgavrielidis@yahoo.com (P. Gavriilidis). |
|
|
|
|
Abstract Terlipressin is a long-acting synthetic analogue of vasopressin, demonstrating several potential benefits in the context of living donor liver transplantation (LDLT). During the recipient hepatectomy, terlipressin reduces the portal flow. Consequently, it may mitigate the extent of bowel congestion following portal vein clamping. By decreasing portal hyperperfusion and hypertension, it protects the graft from further injury and improves renal blood flow. All the above described benefits result in decreased morbidity and improved surgical outcomes [1].
|
|
|
|
|
|
|
|
|
2022, Vol. 21 
